Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

1. A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults

   Wed, 19 Nov 2025 05:00:00 -0000

   Conditions: Healthy Participant
   Interventions: Drug: Ibuzatrelvir
   Sponsors: Pfizer
   Active, not recruiting

2. A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

   Fri, 14 Nov 2025 05:00:00 -0000

   Conditions: COVID-19
   Interventions: Drug: Aluminum Hydroxide Suspension; Biological: Boost-2867; Biological: CpG 7909; Other: Sodium Chloride, 0.9%
   Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
   Not yet recruiting

3. Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

   Thu, 06 Nov 2025 05:00:00 -0000

   Conditions: COVID-19
   Interventions: Biological: NDV-HXP-S-KP.2; Biological: COVID-19 mRNA Vaccine
   Sponsors: CastleVax Inc.
   Recruiting

4. Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

   Fri, 14 Nov 2025 05:00:00 -0000

   Conditions: COVID-19
   Interventions: Biological: PepGNP-COVID19; Other: Sterile Water for Injection
   Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
   Not yet recruiting

5. Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

   Thu, 20 Nov 2025 05:00:00 -0000

   Conditions: Respiratory Tract Infection; Smell Disorder; Influenza; Rhinosinusitis; COVID-19; Depression; Parosmia; Hyposomia; Normosomia; Anosmia
   Sponsors: National Institute on Deafness and Other Communication Disorders (NIDCD)
   Not yet recruiting

6. Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults

   Fri, 14 Nov 2025 05:00:00 -0000

   Conditions: COVID-19
   Interventions: Biological: STX-S
   Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
   Recruiting

7. A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

   Wed, 12 Nov 2025 05:00:00 -0000

   Conditions: COVID-19 Infection
   Interventions: Drug: ibuzatrelvir; Drug: remdesivir; Drug: placebo for ibuzatrelvir; Drug: placebo for remdesivir
   Sponsors: Pfizer
   Recruiting

8. A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19

   Wed, 19 Nov 2025 05:00:00 -0000

   Conditions: COVID-19 SARS-CoV-2 Infection; COVID-19; COVID-19 Infection; Coronavirus Disease 2019 (COVID-19); COVID-19 (Coronavirus Disease 2019); COVID-19 Vaccination; COVID-19 Vaccines; SARS-CoV-2 Infection, COVID19; SARS-CoV-2 Infection, COVID-19
   Interventions: Drug: BNT162b2
   Sponsors: Pfizer
   Active, not recruiting

9. Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction

   Wed, 12 Nov 2025 05:00:00 -0000

   Conditions: Post-Acute COVID-19 Syndrome; Cognitive Dysfunction
   Interventions: Device: Pascal device; Device: Sham Device
   Sponsors: Icahn School of Medicine at Mount Sinai; Humanity Neurotech Inc.
   Active, not recruiting

10. Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine

    Thu, 06 Nov 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated; Biological: Not vaccinated with 2024-2025 formulated COVID-19 vaccine
    Sponsors: Pfizer; CVS Caremark
    Terminated

11. A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

    Tue, 18 Nov 2025 05:00:00 -0000

    Conditions: COVID-19 SARS-CoV-2 Infection
    Interventions: Drug: ibuzatrelvir; Drug: placebo
    Sponsors: Pfizer
    Recruiting

12. A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

    Fri, 14 Nov 2025 05:00:00 -0000

    Conditions: Coronavirus Disease (COVID-19)
    Interventions: Drug: Molnupiravir; Drug: Placebo
    Sponsors: Merck Sharp & Dohme LLC
    Recruiting

13. Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog

    Fri, 07 Nov 2025 05:00:00 -0000

    Conditions: Long COVID
    Interventions: Other: Acute Placebo Visit; Other: Acute Progressive Carbon Dioxide; Other: Acute Intermittent Hypoxia; Other: Training: Progressive Carbon Dioxide Ramping; Other: Training: Intermittent Hypoxic Exposure; Other: Training: Placebo Control
    Sponsors: Mayo Clinic
    Recruiting

14. Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

    Tue, 18 Nov 2025 05:00:00 -0000

    Conditions: COVID-19 Vaccination
    Interventions: Biological: Bretovameran
    Sponsors: Pfizer
    Active, not recruiting

15. The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: Pulmonary Complications; Cardiovascular Complications; Renal Complications; COVID-19
    Interventions: Other: Blood samples; Other: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
    Sponsors: Hellenic Institute for the Study of Sepsis
    Recruiting

16. A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID

    Tue, 18 Nov 2025 05:00:00 -0000

    Conditions: Long Covid-19; PASC Post Acute Sequelae of COVID 19; Brain Fog; Fatigue
    Interventions: Device: rTMS
    Sponsors: University of California, Los Angeles
    Active, not recruiting

17. Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: Pneumonia, Community-Acquired; COVID-19 Pneumonia; Cardiovascular Diseases
    Interventions: Other: Blood samples and Oropharyngeal swab; Other: Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
    Sponsors: Hellenic Institute for the Study of Sepsis
    Recruiting

18. Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

    Tue, 18 Nov 2025 05:00:00 -0000

    Conditions: Birth Outcomes; Safety; Adverse Event Following Immunization
    Interventions: Biological: mRNA COVID-19 vaccine; Biological: IIV4 (quadrivalent inactivated influenza vaccine)
    Sponsors: Duke University
    Active, not recruiting

19. COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study

    Tue, 18 Nov 2025 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Interventions: Biological: Omicron BA.5 SARS-CoV-2 challenge virus
    Sponsors: University of Oxford; Imperial College Healthcare NHS Trust; Chelsea and Westminster Hospital, UK; Royal Free London NHS Trust
    Enrolling by invitation

20. Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults

    Fri, 14 Nov 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: MPV/S-2P
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Completed

21. Dime La VerDAD: Verify, Debunk, and Disseminate

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: Misinformation; Influenza; COVID-19; Vaccine Hesitancy; Communication Research; Health Behavior
    Interventions: Behavioral: Science Communication Curriculum Cohort 1; Behavioral: Science communication curriculum Cohort 2; Behavioral: Science communication curriculum Cohort 3
    Sponsors: University of Chicago; University of Iowa; University of Michigan; Rush University Medical Center; Bedford Research Corporation, Inc.; Tanoma Consulting; National Institute on Minority Health and Health Disparities (NIMHD)
    Recruiting

22. RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM))

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: Long COVID; Long Covid19; Long Covid-19
    Interventions: Behavioral: Structured Pacing; Other: Usual Care
    Sponsors: Duke University; National Heart, Lung, and Blood Institute (NHLBI)
    Active, not recruiting

23. RECOVER-ENERGIZE Platform Protocol

    Fri, 14 Nov 2025 05:00:00 -0000

    Conditions: Long COVID; Long Covid19; Long Covid-19
    Interventions: Behavioral: Personalized Cardiopulmonary Rehabilitation; Behavioral: Structured Pacing; Other: Education; Other: Usual Care
    Sponsors: Duke University; National Heart, Lung, and Blood Institute (NHLBI)
    Completed

24. RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: Long COVID; Long Covid19; Long Covid-19
    Interventions: Behavioral: Personalized Cardiopulmonary Rehabilitation; Other: Education
    Sponsors: Duke University; National Heart, Lung, and Blood Institute (NHLBI)
    Active, not recruiting

25. Stellate Ganglion Block for COVID-induced Parosmia

    Mon, 10 Nov 2025 05:00:00 -0000

    Conditions: COVID-19-Induced Parosmia
    Interventions: Drug: Stellate Ganglion Block; Drug: Placebo Sham Injection
    Sponsors: Washington University School of Medicine
    Completed

26. Connecting Friends and Health Workers to Boost COVID-19 Vaccination in Latino Communities

    Wed, 12 Nov 2025 05:00:00 -0000

    Conditions: COVID-19; Vaccine
    Interventions: Behavioral: REDES; Behavioral: Control
    Sponsors: Johns Hopkins University; National Institute on Minority Health and Health Disparities (NIMHD); Rutgers University
    Recruiting

27. ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

    Tue, 18 Nov 2025 05:00:00 -0000

    Conditions: Covid19
    Interventions: Other: Placebo; Drug: Metformin
    Sponsors: Susanna Naggie, MD; National Center for Advancing Translational Sciences (NCATS); Vanderbilt University Medical Center
    Completed

28. A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

    Mon, 10 Nov 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Experimental: Primary Cohort; Other: Placebo Comparator: Primary Cohort - Placebo
    Sponsors: University of Chicago
    Recruiting

29. Sauna for Long Covid

    Thu, 13 Nov 2025 05:00:00 -0000

    Conditions: Long COVID
    Interventions: Device: whole body hyperthermia
    Sponsors: Massachusetts General Hospital; University of California, San Francisco
    Recruiting

30. Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

    Thu, 06 Nov 2025 05:00:00 -0000

    Conditions: SARS-CoV-2; COVID-19; Post-Acute COVID-19 Syndrome
    Interventions: Biological: Pfizer-BioNTech COVID-19 mRNA vaccine
    Sponsors: Pfizer
    Completed

31. Complementary Self-help Strategies for Patients With Post-COVID-19 Syndrome

    Wed, 19 Nov 2025 05:00:00 -0000

    Conditions: Post-COVID-19 Syndrome
    Interventions: Behavioral: Complementary self-help strategies in addition to treatment as usual; Other: Treatment as usual
    Sponsors: Universität Duisburg-Essen
    Completed

32. Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: Viral Lung Infection and Acute Respiratory Failure
    Interventions: Drug: Tozorakimab; Drug: Placebo
    Sponsors: AstraZeneca
    Recruiting

33. Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Shionogi Protease Inhibitor (S-217622); Drug: placebo
    Sponsors: University of Minnesota; National Institute of Allergy and Infectious Diseases (NIAID)
    Terminated

34. Multidisciplinary Day-hospital Versus Waiting List Management of Post-COVID-19 Persistent Symptoms (ECHAP-COVID)

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: Post COVID-19 Condition
    Interventions: Behavioral: Personalized multidisciplinary day-hospital intervention
    Sponsors: Assistance Publique - Hôpitaux de Paris; URC-CIC Paris Descartes Necker Cochin
    Completed

35. MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: Post-Traumatic Stress Disorder; Adjustment Disorders
    Interventions: Drug: MDMA
    Sponsors: Nautilus Sanctuary; Nautilus Psychiatric Services, PLLC
    Not yet recruiting

36. Home-Based Exercise Tele-Rehabilitation After COVID-19

    Fri, 07 Nov 2025 05:00:00 -0000

    Conditions: Post SARS-CoV2 (COVID-19)
    Interventions: Other: Tele-exercise
    Sponsors: VA Office of Research and Development; Baltimore VA Medical Center; Salem Veterans Affairs Medical Center
    Recruiting

37. COVID-19 Experiences in the SELF Cohort

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute of Environmental Health Sciences (NIEHS)
    Enrolling by invitation

38. Intestinal Microbiota of Patients Hospitalized With Sars-CoV-2

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Other: Fecal sample
    Sponsors: Centre Hospitalier Universitaire de Nīmes
    Active, not recruiting

39. A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

    Wed, 19 Nov 2025 05:00:00 -0000

    Conditions: COVID-19; Coronavirus Disease 2019; Influenza
    Interventions: Biological: COVID-19 Vaccine
    Sponsors: Pfizer; CVS Caremark
    Active, not recruiting

40. Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: COVID-19 Infection; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
    Interventions: Other: Best Practice; Procedure: Discussion; Other: Questionnaire Administration
    Sponsors: M.D. Anderson Cancer Center
    Active, not recruiting

41. Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

    Fri, 07 Nov 2025 05:00:00 -0000

    Conditions: Dysexecutive Syndrome; Post-Acute Sequelae of COVID-19
    Interventions: Device: Active tDCS; Device: Sham tDCS
    Sponsors: Massachusetts General Hospital
    Active, not recruiting

42. COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation

    Wed, 12 Nov 2025 05:00:00 -0000

    Conditions: Breast Cancer, NOS
    Interventions: Other: Questionnaire
    Sponsors: Eastern Cooperative Oncology Group
    Terminated

43. Impact of COVID19 on Asthma Patients in Spain

    Tue, 18 Nov 2025 05:00:00 -0000

    Conditions: Asthma; Covid19
    Interventions: Diagnostic Test: spirometry; Other: Asthma control test
    Sponsors: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Sociedad Española de Neumología y Cirugía Torácica
    Withdrawn

44. Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: Cough; COPD; GERD; Asthma; Tuberculosis; Non-Tuberculous Mycobacterial Pneumonia; COVID-19 Pneumonia
    Interventions: Device: Hyfe Cough Tracker; Device: Hyfe Air
    Sponsors: Clinica Universidad de Navarra, Universidad de Navarra; Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Hyfe Inc
    Completed

45. Korea Comirnaty Post-marketing Surveillance

    Wed, 19 Nov 2025 05:00:00 -0000

    Conditions: COVID-19; Vaccines; Adverse Effects; SARS-CoV-2; Safety
    Interventions: Biological: Tozinameran 12 Years of age and older; Biological: Tozinameran 5 to 11 Years of age; Biological: Tozinameran 6 months to 4 years of age; Biological: Riltozinameran 12 Years of age and older; Biological: Famtozinameran 12 Years of age and older; Biological: Famtozinameran 5 to 11 Years of age; Biological: Raxtozinameran 12 years of age and older; Biological: Raxtozinameran 6 months to 4 years of age
    Sponsors: Pfizer
    Active, not recruiting

46. The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)

    Thu, 06 Nov 2025 05:00:00 -0000

    Conditions: COVID-19 Vaccines
    Interventions: Biological: ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine; Other: Placebo (normal saline); Biological: Astra Zeneca COVID-19 vaccine
    Sponsors: Vinbiocare Biotechnology Joint Stock Company; Arcturus Therapeutics, Inc.
    Completed

47. To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

    Fri, 07 Nov 2025 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection; COVID-19
    Interventions: Biological: BNT162b2; Other: Placebo; Biological: BNT162b2 OMI; Biological: Combination BNT162b2 and BNT162b2 OMI; Biological: Combination (Bivalent) BNT162b2 and BNT162b2 OMI
    Sponsors: BioNTech SE; Pfizer
    Completed

48. Outpatient Treatment With Anti-Coronavirus Immunoglobulin

    Wed, 12 Nov 2025 05:00:00 -0000

    Conditions: COVID; SARS-CoV2 Infection; Covid19
    Interventions: Biological: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG); Other: Placebo
    Sponsors: University of Minnesota; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
    Recruiting

49. Prospective COVID-19 Cohort Study, Dominican Republic

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection; Covid19
    Interventions: Other: Alcohol based hand sanitizer
    Sponsors: Brigham and Women's Hospital; Centers for Disease Control and Prevention; London School of Hygiene and Tropical Medicine; The University of Queensland; Yale University; Broad Institute of MIT and Harvard; Ministerio de Salud Publica y Asistencia Social, Republica Dominicana
    Completed

50. ACTIV-6: COVID-19 Study of Repurposed Medications

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: Covid19
    Interventions: Drug: Ivermectin; Drug: Fluvoxamine; Drug: Fluticasone; Other: Placebo; Drug: Montelukast; Drug: Metformin
    Sponsors: Susanna Naggie, MD; National Center for Advancing Translational Sciences (NCATS); Vanderbilt University Medical Center
    Completed

51. Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: Covid19
    Interventions: Other: Concert; Diagnostic Test: Rapid nasopharyngeal antigen test for Sars-Cov-2; Diagnostic Test: Saliva Sample
    Sponsors: Assistance Publique - Hôpitaux de Paris; PRODISS; WEEZEVENT; URC-CIC Paris Descartes Necker Cochin
    Completed

52. Managed Access Programs for INC424, Ruxolitinib

    Tue, 18 Nov 2025 05:00:00 -0000

    Conditions: Primary Myelofibrosis (PMF); Post Polycythemia Myelofibrosis (PPV MF); Thrombocythemia Myelofibrosis (PET-MF); Severe/Very Severe COVID-19 Illness; Polycythemia Vera (PV); Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD); Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)
    Interventions: Drug: Ruxolitinib
    Sponsors: Novartis Pharmaceuticals
    Available

53. A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19

    Wed, 12 Nov 2025 05:00:00 -0000

    Conditions: Corona Virus Infection
    Interventions: Drug: SIR1-365; Drug: Matching Placebo
    Sponsors: Sironax USA, Inc.
    Completed

54. Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)

    Fri, 14 Nov 2025 05:00:00 -0000

    Conditions: Covid19; ME/CFS; SARS COV2; Novel Coronavirus Infection; Neurocognitive Disorders; Cardiovascular Diseases
    Sponsors: Rush University Medical Center; Yale University; University of Washington; Thomas Jefferson University; University of California, Los Angeles; University of California, San Francisco; University of Texas Southwestern Medical Center; The University of Texas Health Science Center, Houston
    Completed

55. Inflammatory Signal Inhibitors for COVID-19 (MATIS)

    Tue, 18 Nov 2025 05:00:00 -0000

    Conditions: Coronavirus; Covid19; Pneumonia
    Interventions: Drug: Ruxolitinib; Drug: Fostamatinib; Other: Standard of care
    Sponsors: Imperial College London; Imperial College Healthcare NHS Trust; Rigel Pharmaceuticals; Novartis
    Completed

56. Understanding Immunity to the Flu Vaccine in COVID-19 Patients

    Thu, 13 Nov 2025 05:00:00 -0000

    Conditions: Corona Virus Infection; Flu Vaccine; Immunity
    Interventions: Biological: Flu shot
    Sponsors: Stanford University; National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

57. The Effect of the Covid-19 Pandemic Among Operated Patients

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: Covid19; Surgery
    Interventions: Other: COVID-19 infection status; Other: Socioeconomic status
    Sponsors: Karolinska Institutet
    Recruiting

58. Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: Covid19; Dyspnea
    Sponsors: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
    Completed

59. Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic

    Wed, 19 Nov 2025 05:00:00 -0000

    Conditions: COVID-19 Infection
    Interventions: Other: Media Intervention; Procedure: Meditation Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Procedure: Yoga
    Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
    Active, not recruiting

60. Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study

    Wed, 19 Nov 2025 05:00:00 -0000

    Conditions: COVID-19; INTERFERON; NEBULIZATION
    Interventions: Drug: inhaled type I interferon; Drug: WFI water nebulization
    Sponsors: Centre Hospitalier Universitaire, Amiens; CH TOURCOING; CH ARROND DE MONTREUIL; CH SAINT-QUENTIN; CH Compiègne; CH Abbeville; CH VALENCIENNES; Clinique Teissier; University Hospital, Toulouse; University Hospital, Angers; CHU CAEN; Nantes University Hospital
    Active, not recruiting

61. Cardiovascular Consequences After COVID-19

    Wed, 19 Nov 2025 05:00:00 -0000

    Conditions: Cardiovascular Consequences After an Episode of COVID 19
    Interventions: Other: Infectious Disease and Cardiology Clinical Consultations
    Sponsors: Assistance Publique Hopitaux De Marseille
    Terminated

62. Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: SARS-CoV2
    Interventions: Biological: Serology SARS-CoV2; Behavioral: Data collection
    Sponsors: Assistance Publique - Hôpitaux de Paris; URC-CIC Paris Descartes Necker Cochin
    Completed

63. Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

    Thu, 13 Nov 2025 05:00:00 -0000

    Conditions: COVID-19 Disease
    Interventions: Drug: LAU-7b; Drug: Placebo oral capsule
    Sponsors: Laurent Pharmaceuticals Inc.
    Terminated

64. NCI COVID-19 in Cancer Patients, NCCAPS Study

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: COVID-19 Infection; Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
    Interventions: Procedure: Biospecimen Collection; Other: Data Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
    Sponsors: National Cancer Institute (NCI)
    Active, not recruiting

65. Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic

    Mon, 10 Nov 2025 05:00:00 -0000

    Conditions: Perceived Stress; Anxiety; Sleep Disturbance; Burnout; PTSD
    Interventions: Device: Calm Meditation App
    Sponsors: University of Arizona
    Terminated

66. Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children

    Mon, 10 Nov 2025 05:00:00 -0000

    Conditions: Corona Virus Infection; Pediatric Cancer; Adult Children; Cancer
    Sponsors: St. Jude Children's Research Hospital
    Recruiting

67. Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: SARS-CoV-2
    Interventions: Diagnostic Test: Nasal swab; Diagnostic Test: Serum testing
    Sponsors: University Medicine Greifswald; Friedrich Loefler Institute for Animal Health; EUROIMMUN AG
    Completed

68. Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Interventions: Drug: hydroxychloroquine; Drug: azithromycin; Drug: hydroxychloroquine placebo
    Sponsors: Assistance Publique - Hôpitaux de Paris; URC-CIC Paris Descartes Necker Cochin
    Completed

69. In-depth Immunological Investigation of COVID-19.

    Mon, 17 Nov 2025 05:00:00 -0000

    Conditions: Coronavirus Infections
    Interventions: Other: Patient sampling
    Sponsors: Universitaire Ziekenhuizen KU Leuven
    Recruiting

70. Viral Infections in Healthy and Immunocompromised Hosts

    Thu, 20 Nov 2025 05:00:00 -0000

    Conditions: Anogenital Herpes; COVID-19; Herpes Labialis
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting